Differences in the molecular profile of endometrial cancers from British White and British South Asian women

Konstantinos Polymeros,1,2*, David S. Guttery1*, Roger Hew3, Rachael Bishop3, Elizabeth Stannard3, Salvador Macip2, Paul Symonds1, Esther L. Moss1,4*

1 Leicester Cancer Research Centre, University of Leicester, Leicester, England, United Kingdom, 2 Department of Molecular and Cell Biology, University of Leicester, Leicester, England, United Kingdom, 3 Department of Pathology, University Hospitals of Leicester, Leicester, England, United Kingdom, 4 Department of Gynaecological Oncology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, England, United Kingdom

These authors contributed equally to this work.

* em321@leicester.ac.uk

Abstract

Objectives
To identify differences in the mutational profile of endometrial tumours between British White (BW) and South Asian (BSA) women.

Methods
We analysed primary tumours from matched cohorts of British White (BW) and British South Asian (BSA) women resident in Leicestershire diagnosed with EC. Next Generation Sequencing was performed to investigate mutational differences in a panel of 10 genes previously identified as being commonly mutated in EC. The presence of somatic Mismatch Repair (MMR) gene deficiencies was determined by immunohistochemistry.

Results
In total, 57 tumours (27 BSA and 30 BW) were sequenced. There was no significant difference in the overall mutation frequency of the 10 genes analysed; however, numerous differences were observed between the groups. There was a positive association between PIK3CA and PTEN mutations in the BSA group, with 78% of PIK3CA-mutant tumours harbouring a PTEN mutation, whereas only 11% of PIK3CA wild-type (wt) tumours were PTEN mutant positive (p = 0.0012). In BW women, 90% of ARID1A mutant tumours had co-existent PI3K pathway mutations versus 50% of wild-type (wt) ARID1A patients (p = 0.0485). This trend was not significant in the BSA group (p = 0.66). The age at diagnosis was significantly higher in the BW group with a somatic MMR gene deficiency compared to those with no deficiency (72.8 years versus 59.6 years, p = 0.007), whereas this difference was not seen in the BSA group (64 years versus 60 years, p = 0.37).
Conclusion

We have identified differences in the mutational profile of primary EC tumours from BW and BSA women. Further research is needed to confirm these findings and to explore their potential implications for early detection, treatment response and prognosis.

Introduction

Internationally endometrial cancer (EC) is the second most common gynaecological malignancy with an estimated 382,069 new cases and 89,929 deaths worldwide in 2018 [1]. The incidence of endometrial cancer (EC) is typically higher in high-income countries, as compared to low-income countries however, the picture is changing with India in particular having the highest annual increase in EC incidence internationally between 2005 and 2007, a rise of 13% [2].

The issue of investigating ancestry and genetics in research is challenging due to the concept of race being confused or influenced by the interaction of environment and culture, as well as heterogeneity within populations [3]. Although it has been proposed that the use of race as a surrogate marker for measurable genetic differences should be avoided [4], it is acknowledged that there is utility when investigating the interplay of genes and environmental factors [5] and with a "biological correlate relevant to the disease" [6]. Much research has already been conducted in to the racial/ethnic differences in EC, predominantly from the USA, focusing on Black or African American (BoAA) and Caucasian women. A lower incidence of EC in BoAA women has been reported, as compared to Caucasian women [7–9], however, with a significantly worse prognosis [10]. Although, inequality in healthcare has been proposed as one reason for this difference it does not explain why BoAA women have greater propensity for developing serous subtypes as compared to other racial groups. The TCGA database has been utilised to look into this further and distinct molecular groupings have been identified in the EC tumours from BoAA and Caucasian women [11]. This supports the view that the clinical differences seen between BoAA and Caucasian women are due to underlying genetic differences, with a higher rate of TP53 mutations and ERBB2 amplification in tumours from BoAA women compared to tumours from Caucasian women [12,13], whereas the opposite is true for the frequency of PTEN mutations [14].

Limited evidence regarding the mutational landscape of EC exists for other geographic populations, with one of the least studied groups being Asian women. The categorisation of ‘Asian’ heritage in the medical literature is fraught with challenges and misconceptions, with Asia being the descriptive term for a large geographical area composed of many different cultural and environmental situations, which may share very few similarities. Therefore using the collective term Asian for women for the purposes of analysis could give misleading results and emphasises the need to be highly descriptive and avoid broad categories [15]. It could help to explain reported differences between data from the USA where the incidence of EC in Asian residents was found to be 40% less compared to the Caucasian population [8], whereas a UK study comparing White British with South Asian women living in the UK showed no difference (incidence rate ratio 0.90 vs 1, CI 0.81–1.01) [16]. One finding consistently reported however, is that the age at diagnosis is significantly lower in Asians as compared to Caucasian populations [17,18].

The aim of our study was to address this lack of evidence by investigating the mutational profile of genes commonly associated in the pathogenesis of EC in primary tumour specimens.
from women from two groups resident in Leicestershire: British White (BW) and Asian/Asian British–Indian/Pakistani, which we will refer to collectively as British South Asian (BSA). BSA is an accepted term that refers to a person whose ancestry originates in the Indian subcontinent, and who identifies with, or is identified with, their host country [19].

Materials and methods

Ethical approval for the study was granted by Yorkshire and The Humber—Bradford Leeds Research Ethics Committee (REC reference number: 15/YH/0510). Women diagnosed with EC at the University Hospitals of Leicester between February 2016 and February 2018 were recruited. Informed written consent was obtained prior to participation and all underwent primary surgery, including hysterectomy. Participants’ ethnicity was self-designated using the National Office of Statistics for the decennial UK National Census classification.

Sixty of the patients recruited (30 BW and 30 BSA) who had confirmed histological diagnosis of EC were selected after being matched in terms of risk for adjuvant therapy using the ESGO-ESMO-ESTRO classification [20]. Based on this consensus document, patients with EC were categorised based on their risk of developing a recurrence to low, intermediate, high-intermediate, high, advanced and metastatic groups using FIGO stage, grade, histology, myometrial invasion, lymphovascular space involvement and residual disease following surgery. In total, 15 ‘low-risk’ and 15 intermediate/high-risk tumours were analysed from both the BW and BSA groups.

DNA extraction

Formalin-Fixed, Paraffin Embedded (FFPE) blocks of the primary tumour were obtained. Following Haematoxylin-Eosin staining (H&E), a Consultant Pathologist marked a high density area of tumour and a 1.5mm core biopsy was performed. DNA was extracted using the QIAamp Generead DNA FFPE Tissue Kit (Qiagen) as per manufacturer’s instructions.

Targeted Next Generation Sequencing (tNGS)

The Ion AmpliSeq designer software (https://www.ampliseq.com) was used to generate a custom 190 amplicon Ion AmpliSeq panel for analysis of hotspot regions in 10 genes commonly mutated in EC (ARID1A, CTNNB1, FBXW7, KRAS, PIK3CA, PIK3R1, POLE, PTEN, PPP2R1A, TP53) based on publicly available databases (https://portal.gdc.cancer.gov/) [21]. The panel was designed to contain two pools, against FFPE tissue, with amplicons ranging from 125–175 bp. Initial library preparation was performed using 20 ng of FFPE DNA. Samples were sequenced on a 318 chip using the Ion PGM Sequencer according to manufacturers’ instructions. Sequencing data was accessed and analysed through the Torrent Suite v5.6.0. All mutations with a quality score below 100 were omitted and all variants detected in the first or last 10 bases of an amplicon were omitted as likely mispriming events [22]. ANNOVAR [23] was used to annotate all mutations with refGene ID, functional consequence (e.g., non-synonymous), and functional predictions using SIFT [24], Polyphen-2 [25] and MutationTaster [26]. Known germline variants without pathological consequence were omitted from the analysis. All variants detected were also manually confirmed across all samples using the Integrated Genomics Viewer 2.3 [27,28]. The mutant allele frequency (termed AF) was calculated as the proportion of total reads at a site, which contained the variant allele (e.g. if you have 200 reads in total and 8 of them have the variant, then the AF is (8/200) x 100 = 4%). TIER 1 and TIER2 drivers were identified using the cancer genome interpreter for SNVs, INDELs, and SCNA, with potential treatments analysed using the web-based analysis function at https://www.cancergenomeinterpreter.org.
Immunohistochemistry

Immunohistochemistry was conducted using a Dako Autostainer in order to determine the presence of a somatic mutation within the four mismatch repair (MMR) genes associated with EC (\textit{MSH2, MSH6, MLH1} and \textit{PMS2}). The 5μM sections were incubated with the following primary antibodies; Monoclonal Mouse MLH1 (clone ES05), Monoclonal Mouse MSH2 (clone FE11), Monoclonal Rabbit MSH6 (clone EP49) and Monoclonal Rabbit PMS2 (clone EP51), all obtained from Dako (Santa Clara, CA 95051, USA). Antigen retrieval was performed in a Dako PTlink using a high pH target retrieval solution. Following a 30 minutes incubation with the primary antibodies, visualisation was carried out using the Dako enVision Flex + detection system for MSH6 and PMS2, with a mouse linker for MLH1 and MSH2. On-slide control tissue was used, along with internal control of background endometrium. Results were independently assessed by two pathologists.

Statistical analysis

Chi-square and Fisher’s exact tests were used to compare categorical variables. Analysis was two-sided and differences were considered to be statistically significant at \(p < 0.05\). All analyses were performed using GraphPad Prism software, version 7.0 (GraphPad Software, Inc, CA, USA).

Results

The mean body mass index (BMI) was lower in the BSA compared to the BW groups (32.5kg/m\(^2\) versus 37.8kg/m\(^2\), \(p = 0.0253\)), however the incidence of diabetes was more than double, 44% versus 20% respectively (\(p = 0.08\)) (Table 1). The BW patients with low-risk disease were significantly younger at diagnosis compared to intermediate- and high-risk patients (54.1 vs. 70.4 years old, \(p < 0.0001\)) whereas this difference was not significant in the BSA group (59.4 vs. 63 years old, \(p = 0.39\)).

Table 1. Clinical and demographic data for the participants of the study whose tumours were sequenced. P values were calculated using Student’s t-test (unpaired) for age and BMI, Fisher’s exact test for histology and diabetes and Chi-Square test for stage and grade.

| Group          | British White | British South Asian | \(p\) value |
|----------------|---------------|---------------------|-------------|
| \(n\)          | 30            | 27                  |             |
| Mean age (range) | 62.3 (48–84) | 61.2 (36–77)        | 0.7         |
| Mean BMI (range) | 37.8 (19–65) | 32.5 (23–52.2)      | \(0.0253\) |
| Histology      |               |                     | 0.4         |
| Endometrioid (%) | 28 (93%)     | 23 (85%)            |             |
| Serous (%)     | 2 (7%)        | 4 (15%)             |             |
| Stage (FIGO)   |               |                     | 0.88        |
| 1              | 25 (83%)      | 23 (85%)            |             |
| 2              | 3 (10%)       | 3(10%)              |             |
| 3              | 2 (7%)        | 1 (5%)              |             |
| Grade          |               |                     | 0.37        |
| 1              | 20            | 13                  |             |
| 2              | 7             | 10                  |             |
| 3              | 3             | 4                   |             |
| Diabetes (%)   |               |                     | 0.08        |
| Yes            | 6 (20%)       | 12 (44%)            |             |
| No             | 24 (80%)      | 15 (56%)            |             |

https://doi.org/10.1371/journal.pone.0233900.t001
Gene mutations

There were a total of 129 non-synonymous mutations in the 10 genes analysed, a mean of 2.3 per case (Table 2). For full details of each mutation per patient, see S1 Table. A few associations were seen across the whole cohort, in particular the presence of TP53 mutations and older age at diagnosis (72.5 vs 60.5 years, p = 0.008). A similar association was seen between PIK3CA mutations and age (65.9 vs 59.3 years, p = 0.0245). No differences were identified in the incidence of non-synonymous mutations in these ten genes between the two groups although differences were seen in associations. In the BW cases, ARID1A mutations co-existed with PI3K pathway mutations (defined as mutations in either PIK3CA, PIK3R1 or PTEN), as 90% (9/10) of ARID1A mutation carriers had a concurrent PI3K pathway mutation versus 50% (10/20) of wild-type (wt) ARID1A patients (p = 0.0485). This was not seen in the BSA cases (67% versus 52%, p = 0.66). Additional analysis was performed, including logistic regression, to adjust for BMI, grade and histology and this did not alter the result.

In the BSA cases, somatic CTNNB1 mutations tended to be younger at diagnosis (mean age 55.6 years compared to 63.5 for their wild type counterparts, p = 0.077), a finding not seen in the BW cohort (63.3 years for somatic CTNNB1 mutation carriers compared to 62.1 for wt-CTNNB1, p = 0.85). 92% of the CTNNB1 mutations (12/13) identified in both groups were found in exon 3, from codon 32 to 41 and all of them were missense. The majority of these alterations (67%, 8/12) affected Serine or Threonine residues (S33, S37 and T41). Ninety-three percent (13/14) of FBXW7 mutations detected were missense as were all six KRAS mutations, with three due to a substitution of glutamine to histidine (Q61H), a mutation mainly reported in colorectal malignancies [29]. Interestingly, all four KRAS-mutant tumours in the BW group had co-existent PI3K pathway mutations versus only 38% (10/26) of wt-KRAS cases (p = 0.0365). Only one BSA case contained a KRAS mutation, and therefore no comparison was possible.

Across the whole cohort, there was a total of 30 PIK3CA mutations, all missense, of which 10 were located in the p85-binding domain of the gene, with 4 of the 10 being a gain-of-function R88Q mutation (all identified in BW group). Another common mutation was the E545 in the helical domain (13% of the total, n = 4, two BW and two BSA). There was a strong, positive association between PIK3CA and PTEN mutations in the BSA, but not BW, group in which 78% (7/9) of PIK3CA-mutant tumours were also carrying a PTEN mutation versus only 11% (2/18) for wt-PIK3CA tumours (p = 0.0012). Interestingly, PIK3CA-mutant patients in the BW group were significantly older at diagnosis (mean age 68.7 years versus 58 for wt-PIK3CA, p = 0.0077) but this was not seen in BSA group.

PTEN mutations in the BW group were more likely to localize in the phosphatase catalytic domain of the gene (53%, 8/15), whereas, in the BSA group the majority of PTEN mutations was observed in the C2 domain of the gene (64%, 7/11). These differences however did not reach significance (p = 0.168).

As BMI was the only variable significantly different between the BW and BSA groups further analysis was performed dividing the whole cohort into BMI <35kg/m² and >35kg/m². There was no significant difference in the number of mutations in the ten genes tested nor in the rates of MMR deficiency in these two groups. The only association identified was PIK3CA mutations co-existed more frequently with PTEN mutations in the <35kg/m² BMI group (9/13, 69% of PIK3CA-mutant patients had co-existent PTEN mutations compared to 4/16, 25% of wt-PIK3CA, p = 0.027), which was not the case in the >35 kg/m² BMI cohort (4/8, 50% versus 5/20, 25% respectively, p = 0.37).
Table 2. Non-synonymous mutations in the 10 genes tested in all the tumours (n = 57). Coloured cells represent a mutated gene, the number indicating the number of non-synonymous mutations identified within the gene. MMR deficient tumours are indicated by coloured cells. The mutation frequency between the two groups (British White (BW) and British South Asian (BSA) were calculated using Fisher’s exact test.

| Patient | Stage | Grade | Histology | ARID1A | CTNNB1 | FBXW7 | KRAS | PIK3CA | PIK3R1 | POLE | PPP2R1A | PTEN | TP53 | MMR |
|---------|-------|-------|-----------|--------|--------|--------|-------|--------|--------|------|---------|------|------|-----|
| BW1     | 1A    | 1     | Endometroid | 1      |        |        | 1     | 2      |        | 1    | 2       |      |      |     |
| BW2     | 1A    | 1     | Endometroid | 1      | 1      |        | 1     | 1      |        | 1    |         |      |      |     |
| BW3     | 1A    | 1     | Endometroid |        |        |        | 1     | 1      |        |      |         |      |      |     |
| BW4     | 1A    | 3     | Mixed (endometroid+serous) |        |        |        | 1     |        |        |      |         |      |      |     |
| BW5     | 1B    | 2     | Endometroid | 1      |        |        | 2     |        |        |      |         |      |      |     |
| BW6     | 1A    | 1     | Endometroid | 1      | 1      |        | 1     |        |        | 1    |         |      |      |     |
| BW7     | 2     | 1     | Endometroid |        |        |        | 1     | 1      |        |      |         |      |      |     |
| BW8     | 1A    | 1     | Endometroid | 1      |        |        | 2     | 1      | 1      |      |         |      |      |     |
| BW9     | 1A    | 1     | Endometroid |        |        |        | 2     | 1      | 1      |      |         |      |      |     |
| BW10    | 1A    | 1     | Endometroid | 1      |        |        |        |        | 1      |      |         |      |      |     |
| BW11    | 1B    | 1     | Endometroid |        |        |        | 2     | 4      | 1      |      |         |      |      |     |
| BW12    | 1B    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW13    | 1B    | 2     | Endometroid |        |        |        | 1     | 1      |        |      |         |      |      |     |
| BW14    | 3B    | 3     | Endometroid | 1      |        |        | 1     | 1      | 1      | 1    | 1       |      |      |     |
| BW15    | 1B    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW16    | 1A    | 3     | Endometroid |        |        |        |        |        |        |      |         |      |      |     |
| BW17    | 1A    | 1     | Endometroid | 1      |        |        |        |        | 1      |      |         |      |      |     |
| BW18    | 1B    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW19    | 1A    | 1     | Endometroid | 1      |        |        |        | 1      | 1      | 1    |         |      |      |     |
| BW20    | 2     | 2     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW21    | 1A    | 1     | Endometroid | 1      |        |        |        |        | 1      |      |         |      |      |     |
| BW22    | 1A    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW23    | 3A    | 2     | Endometroid |        |        |        | 1     | 2      | 1      |      |         |      |      |     |
| BW24    | 1A    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW25    | 2     | 1     | Endometroid |        |        |        |        | 1      | 1      | 2    |         |      |      |     |
| BW26    | 1B    | 2     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW27    | 1A    | 2     | Endometroid |        |        |        | 1     |        | 1      |      |         |      |      |     |
| BW28    | 1B    | 2     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BW29    | 1A    | 3     | Mixed (serous and clear cell) | 1      |        |        | 1     | 1      | 1      |      |         |      |      |     |
| BW30    | 1A    | 1     | Endometroid |        |        |        |        |        | 1      |      |         |      |      |     |
| BSA1    | 1A    | 2     | Endometroid |        |        |        |        | 1      |        | 2    |         |      |      |     |
| BSA2    | 1A    | 2     | Endometroid |        | 1      |        | 1     |        |        |      |         |      |      |     |
| BSA3    | 2     | 3     | Serous |        | 1      |        |        | 1      |        |      |         |      |      |     |
| BSA4    | 1A    | 1     | Endometroid |        | 2      |        |        | 2      |        |      |         |      |      |     |
| BSA5    | 1A    | 2     | Endometroid |        |        |        | 1      | 1      |        |      |         |      |      |     |
| BSA6    | 1A    | 2     | Endometroid |        |        |        | 1      |        |        |      |         |      |      |     |
| BSA7    | 1B    | 1     | Endometroid |        |        |        | 1      | 1      | 2      |      |         |      |      |     |
| BSA8    | 1A    | 3     | Clear cell |        |        |        |        |        |        |      |         |      |      |     |
| BSA9    | 1B    | 2     | Endometriot |        |        |        |        |        |        | 1    |         |      |      |     |
| BSA10   | 3C1   | 3     | Serous |        |        |        |        |        |        |      |         |      |      |     |
| BSA11   | 1A    | 1     | Endometriot |        |        |        | 1      | 1      |        |      |         |      |      |     |
| BSA12   | 1B    | 1     | Endometriot |        |        |        |        |        | 1      |      |         |      |      |     |
| BSA13   | 1A    | 1     | Endometriot |        |        |        |        |        |        |      |         |      |      |     |
| BSA14   | 1B    | 2     | Endometriot |        |        |        | 1      | 1      |        |      |         |      |      |     |
| BSA15   | 1B    | 2     | Endometriot |        |        |        | 1      | 1      |        |      |         |      |      |     |
| BSA16   | 1A    | 1     | Endometriot | 1      |        |        | 1      | 1      | 1      | 1    |         |      |      |     |

(Continued)
A quarter of tumours (14/57) exhibited a deficiency in at least one of the MMR genes (Table 3). There was no difference in the presence of mutations between the BW and BSA group (20% vs 30%, p = 0.54), with the most common mutation MLH1/PMS2 being identified in 4 cases (67%) in the BW group and 7 cases (88%) in the BSA group. MSH6 mutations were identified in one BW and one BSA case and a MSH2/MSH6 mutation was only seen in one BW case. The age at diagnosis was significantly higher in the BW group with a somatic MMR gene deficiency compared to those with no deficiency (72.8 years versus 59.6 years, p = 0.007), whereas this difference was not seen in the BSA group (64 years versus 60 years, p = 0.37).

Examining associations between MMR gene deficiencies and the non-synonymous mutations described previously showed that within the BSA group, there was a negative association between MMR deficiency and \textit{CTNNB1} mutations as none of the eight \textit{CTNNB1}-mutant

### Table 2. (Continued)

| Patient | Stage | Grade | Histology   | ARID1A | CTNNB1 | FBXW7 | KRAS | PIK3CA | PIK3R1 | POLE | PPP2R1A | PTEN | TP53 | MMR |
|---------|-------|-------|-------------|--------|--------|-------|------|--------|--------|------|---------|------|------|-----|
| BSA17   | 1A    | 3     | Serous      |        |        |       |      |        |        |      |         |      |      |     |
| BSA18   | 1A    | 1     | Endometrioid|        |        |       |      |        |        |      |         |      |      |     |
| BSA19   | 1A    | 1     | Endometrioid|        | 1      |       |      |        |        |      |         |      |      |     |
| BSA20   | 2     | 2     | Endometrioid|        |        | 2     | 2    | 2      | 1      |      |         |      |      |     |
| BSA21   | 2     | 2     | Endometrioid|        | 2      | 2    | 2    | 1      |        |      |         |      |      |     |
| BSA22   | 1A    | 1     | Endometrioid|        |        |       |      |        |        |      |         |      |      |     |
| BSA23   | 1B    | 1     | Endometrioid|        |        | 1     | 1    |        |        |      |         |      |      |     |
| BSA24   | 1B    | 1     | Endometrioid|        | 1      |       |      |        |        |      |         |      |      |     |
| BSA25   | 1A    | 1     | Endometrioid|        |        |       |      |        |        |      |         |      |      |     |
| BSA26   | 1A    | 1     | Endometrioid|        |        | 1     | 1    |        |        |      |         |      |      |     |
| BSA27   | 1A    | 2     | Endometrioid|        |        |       |      |        |        |      |         |      |      | 1   |

**Group comparison p values**

|                     | 0.39 | 0.19 | 0.75 | 0.35 | 0.78 | 0.24 | 0.67 | 0.47 | 0.59 | 1.00 |

### Table 3. Patient demographics and MMR protein expression (MLH1/MSH2/MSH6/PMS2) on immunohistochemistry.

|                     | MMR proficient n = 43 | MMR deficient n = 14 | p value |
|---------------------|-----------------------|----------------------|---------|
| Grouping            |                       |                      | 0.54    |
| BW                  | 24 (56%)              | 6 (43%)              |         |
| BSA                 | 19 (44%)              | 8 (57%)              |         |
| Mean age            | 59.8                  | 67.8                 | 0.014   |
| Mean BMI            | 36.5                  | 31.5                 | 0.066   |
| Diabetes status     |                       |                      | 0.51    |
| Diabetic            | 15 (35%)              | 3 (21%)              |         |
| Non-diabetic        | 28 (65%)              | 11 (79%)             |         |
| Risk group* (%)     |                       |                      | 0.55    |
| Low                 | 23 (53%)              | 6 (43%)              |         |
| Intermediate-High   | 20 (47%)              | 8 (57%)              |         |
| Grade (%)           |                       |                      | 0.16    |
| 1                   | 26 (63%)              | 6 (43%)              |         |
| 2                   | 10 (23%)              | 7 (50%)              |         |
| 3                   | 5 (14%)               | 1 (7%)               |         |

* Risk groups for adjuvant therapy using the ESGO-ESMO-ESTRO classification (20)

https://doi.org/10.1371/journal.pone.0233900.003
patients was MMR-deficient versus 42% (8/19) of $CTNNB1$-wt tumours ($p = 0.06$). There was no such trend in the BW cohort as 25% (1/4) of patients with a somatic $CTNNB1$ mutation was MMR deficient compared to 19% (5/26) of wt-$CTNNB1$ patients ($p = 1$). A similar negative correlation was seen in the BSA group between MMR deficient tumours and $FBXW7$ mutations (0/7, 0% of $FBXW7$-mutant patients had concomitant MMR deficiency versus 8/20, 40% on the $FBXW7$-wt patients, $p = 0.068$). The same was not seen in BW women as 17% (1/6) of $FBXW7$-mutant patients were MMR deficient compared to 21% (5/24) of wt-$FBXW7$ women ($p = 1$).

**Discussion**

In this study we have explored the mutational landscape of EC in a previously under investigated population. Leicester is an ethnically diverse region with 28.3% of the Leicester population identifying as ‘Indian’ in the 2011 National census ($n = 93,335$) [30]. By selecting a population living in the same region, being treated within the ‘free at the point of need’ NHS we have attempted to address the differences that may result from access to health care and geographical location, although it was not possible to determine the duration of residence in the UK of the women in the BSA group. The BSA population is of interest since the leading risk factors for EC are obesity and diabetes, both of which have been shown to have different thresholds in the BSA as compared to White Europeans [31]. BSA women have lower obesity cut-off points for the development of dysglycemia, 21.5kg/m$^2$ compared to 30kg/m$^2$ for White European women, which could impact on prevention strategies and identifying women at risk of EC. Unlike previous epidemiological studies on EC in Asian women, our BSA cohort was very homogeneous, the majority of women were of Guajarati Indian heritage [32], and despite the sample size being relatively small, it is larger than the paradigm shifting TCGA EC study [21], which included only 20 Asian patients, with no other geographical definitions.

The 10 genes of interest were selected based on their frequency in EC, for which there is a wealth of evidence [33], and their potential significance in guiding personalised therapy. We have shown a strong co-existence of $PIK3CA$ and $PTEN$ mutations in the BSA group, which was not seen in the BW group. The correlation between $PIK3CA$ and $PTEN$ has been reported previously in EC in a cohort of cases from Japan [34] and might have clinical implications since a large study of a variety of solid tumours (mainly colorectal and ovarian) showed that patients with $PIK3CA$ and/or $PTEN$ mutations had a significantly greater partial response to $PI3K/mTOR$ inhibition [35] compared to wt-tumours of these two genes. Our results therefore raise the possibility of greater efficacy of these treatments in BSA, as compared to BW, populations.

Previous studies have shown an association between $ARID1A$ and mutations in the $PI3K$ pathway with $ARID1A$ mutations independently increasing the downstream activation of $PI3K$ pathway [36]. We have confirmed this finding in the BW but not in the BSA group, with BW cases being more likely to ‘need’ $ARID1A$ suppression for $PI3K$ pathway activation whereas cases in the BSA group were more likely to have an activated $PI3K$ pathway due to co-existence of $PIK3CA$ and $PTEN$ mutations. Also, it has recently been shown that $ARID1A$ mutations can render cancer cells sensitive to glutathione and glutamate-cysteine ligase synthetase catalytic subunit (GCLC) inhibitors [37], while they also increase the sensitivity of cancer cells to PI3K inhibitors [38]. It can therefore be proposed that combining PI3K with GCLC inhibitors could be an effective strategy for the 30% of endometrial cancers carrying an $ARID1A$ mutation. Our data therefore support the need for a personalised approach to identify the presence of mutations in different populations before embarking on trials investigating novel drug combinations.
Studies in ovarian clear cell carcinoma (OCCC) have shown higher prevalence of the disease in East Asia compared to North America and Europe [39]. Since one of the most frequent mutations in OCCC is ARID1A, higher rates of such genetic alterations in the BSA cohort could be expected. On the contrary, we have shown no difference in the rate of ARID1A mutations between the two groups, which is consistent with our previous analysis of TCGA cohort (11). One possible explanation is that many epidemiological studies in OCCC were conducted in Japan, a very different phylogenetic and environmental population as compared to South Asia.

Identifying the MMR status is becoming increasingly important in EC since it guides screening for potential Lynch Syndrome cases but also drug therapy options, for example checkpoint inhibitors such as Pembrolizumab. Our reported rate of somatic MMR mutations (25%) is very similar to recent reports in the literature [40,41]. There was no difference in the prevalence of MMR deficiency in the two groups however, the higher age at diagnosis in the BW group supported the view that MMR testing should be universal rather than focused on the younger EC population. The association between older age at diagnosis and MMR deficiency has been previously shown in studies on colorectal cancer and confirms our findings [42,43]. Our study reports a trend associating obesity with decreased rates of MMR deficiency (mean BMI 36.5 for MMR proficient tumours compared to 31.5 for MMR deficient, p = 0.066), and although this trend is not significant, this association has been reported in both colorectal and endometrial cancer studies [42,44]. Reasons for this association are not clear, although previous studies in colorectal cancer had shown that hyperestrogenemia reduces the risk of MMR deficiency, and this may explain the higher incidence of MSI in thin and elderly patients [45]. With aging, estrogen receptors (ER) in colonic cells hypermethylate, leading to reduced ER expression, which subsequently increases the carcinogenic potential of the colonic cells [46]. It is unknown as to whether the same mechanism occurs in endometrial cells and could be the focus of future studies.

There was a negative association between CTNNB1 mutations and MMR deficiency in our cohort, which supports evidence from previous larger study that showed that CTNNB1 mutations were less frequent in MSI positive tumours [47], although the mechanism accounting for this negative correlation has yet to be elucidated.

The main limitation of our study was the relatively small number of cases analysed. The sample size meant that it was not possible to adjust for all clinico-pathological factors and it is possible that significant associations have not been identified due to lack of statistical power. The likelihood of the relatedness of the BSA, although possible, is unlikely given Leicester’s large South Asian population and a similar possibility could be raised for the BW population.

In summary, we have identified differences in the molecular profile of ten genes associated with EC in tumours from BW and BSA women. Further research is needed to confirm these findings in a larger population and to explore their potential implications for treatment response and prognosis.

**Supporting information**

**S1 Table.**
(XLSX)

**Acknowledgments**

This study was supported by the Experimental Cancer Medicine Centre (ECMC). We would also like to thank the patients and clinicians from the University Hospitals of Leicester who...
supported this study and the Centre for Black and Minority Ethnic (BME) Health, University of Leicester for reviewing the manuscript.

**Author Contributions**

**Conceptualization:** David S. Guttery, Esther L. Moss.

**Data curation:** Konstantinos Polymeros, David S. Guttery, Rachael Bishop, Elizabeth Stannard.

**Formal analysis:** Konstantinos Polymeros, David S. Guttery.

**Funding acquisition:** David S. Guttery, Esther L. Moss.

**Investigation:** David S. Guttery, Roger Hew, Rachael Bishop, Elizabeth Stannard.

**Methodology:** David S. Guttery.

**Resources:** Roger Hew, Salvador Macip, Esther L. Moss.

**Supervision:** David S. Guttery, Salvador Macip, Paul Symonds, Esther L. Moss.

**Writing – original draft:** Konstantinos Polymeros.

**Writing – review & editing:** David S. Guttery, Roger Hew, Rachael Bishop, Elizabeth Stannard, Salvador Macip, Paul Symonds, Esther L. Moss.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018 Sep 12.

2. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. Journal of the National Cancer Institute 2018 Apr 1; 110(4):354–361. https://doi.org/10.1093/jnci/djx214 PMID: 29045681

3. Yudell M, Roberts D, DeSalle R, Tishkoff S. SCIENCE AND SOCIETY. Taking race out of human genetics. Science (New York, N.Y.) 2016 Feb 5; 351(6273):564–565.

4. Bevan D. Genes, race and drugs. Clinical and investigative medicine. Medecine clinique et experimentale 2004; 27(1):5. PMID: 15061577

5. Williams HC. Have You Ever Seen an Asian/Pacific Islander? Archives of Dermatology 2002 May 1; 138(5):673–674. https://doi.org/10.1001/archderm.138.5.673 PMID: 12020231

6. Ethnicity, Race, And Culture: Guidelines For Research, Audit, And Publication. BMJ: British Medical Journal 1996 Apr 27; 312(7038):1094. PMID: 8616423

7. Setiawan V,Wendy, Pike C, Kolonel N, Nomura M, Goodman T, et al.—Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 2007; 165:262–70. https://doi.org/10.1093/aje/kwk010 PMID: 17090617

8. Jamison P-, Noone A, Ries L-, Lee N-, Edwards B-. Trends in Endometrial Cancer Incidence by Rates and Histology with a Correction for the Prevalence of Hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 2013 February; 22(2).

9. Cote M-, Ruterbusch J-, Olson S-, Lu K-, Ali-Fehmi R-. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiology, Biomarkers and Prevention 2015; 24(9).

10. Sherman M-, Devesa S-. Analysis of Racial Differences in Incidence, Survival, and Mortality for Malignant Tumors of the Uterine Corpus. Cancer 2003; 98(1):176. https://doi.org/10.1002/cncr.11484 PMID: 12833470

11. Guttery DS, Blighe K, Polymeros K, Symonds RP, Macip S, Moss EL. Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas. 2018 Mar 30.

12. Clifford SL, Kaminetskys CP, Cirisano FD, Dodge RS,John T., Clarke-Pearson DL, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. American Journal of Obstetrics & Gynecology 1997 June; 176(6):229S–232S.
13. Santin D, Bellone S, Siegel R, Palmieri M, Thomas M, Cannon J, et al.—Racial differences in the over-expression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 2005; 192:813–8. https://doi.org/10.1016/j.ajog.2004.10.605 PMID: 15746676

14. Maxwell GL, Risinger Ji, Hayes KA, Alvarez AA, Dodge RK, Barrett JC, et al.—Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res 2000; 6:2999–3005. PMID: 10955777

15. Smart Andrew, Tutton Richard, Martin Paul, Ellison George T. H., Ashcroft Richard. The Standardization of Race and Ethnicity in Biomedical Science Editorials and UK Biobanks. Social Studies of Science 2008 Jun 1,; 38(3):407–423. https://doi.org/10.1177/0306312707083759 PMID: 19069078

16. Shirley M., Barnes I., Sayeed S., Finlayson A., Ali R.- Incidence of breast and gynaecological cancers by ethnic group in England, 2001–2007: a descriptive study. BMC Cancer 2014; 14(979).

17. Mahdi H, Schlick CJ, Kowk L, Moslemi-Kebria M, Michener C. Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women. Gynecologic oncology 2014 Feb; 132(2):443–449. https://doi.org/10.1016/j.ygyno.2013.11.028 PMID: 24316310

18. Zhang M, Cheung M, Osann K, Lee M, Lin Gomez S, Whitemore A, et al. Improved Survival of Asians With Corpus Cancer Compared With Whites: An Analysis of Underlying Factors. Obstetrics & Gynecology 2006 Feb; 107(2, Part 1):329–335.

19. Office for National Statistics. Cancer Registration Statistics, England: First release, 2014. 2016.

20. Colombo N-, Creutzberg C-, Amant F-, Bosse T-, Gonzalez-Martín A-, Ledermann J-, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer. International Journal of Gynecological Cancer 2016; 26(1).

21. TCGA RN. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73. https://doi.org/10.1038/nature12113 PMID: 23636398

22. Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clinical chemistry 2015; 61(7):974. https://doi.org/10.1373/clinchem.2015.238717 PMID: 25979954

23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 2010 Sep; 38(16):e164. https://doi.org/10.1093/nar/gkq603 PMID: 20601685

24. Ng PC, Kumar P, Henikoff S. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protocols 2009 Jun; 4(8):1073–1081.

25. Peshkin L, Bork P, Sunyaev SR, Adzhubei IA, Gerstein M, Sunyaev SR, et al. A method and server for predicting damaging missense mutations. Nature Methods 2010 Apr; 7(4):248–249. https://doi.org/10.1038/nmeth0410-248 PMID: 20354512

26. Jana Marie Schwarz, David N Cooper, Markus Schuelke, Dominik Seelow. MutationTaster2: mutation prediction for the deep-sequencing age. Nature Methods 2014 Apr 1,; 11(4):361–362. https://doi.org/10.1038/nmeth.2890 PMID: 24681721

27. Thorvaldsdóttir H, Lander ES, Guttmman M, Winckler W, Mesirov JP, Robinson JT, et al. Integrative genomics viewer. Nature Biotechnology 2011 Jan; 29(1):24–26. https://doi.org/10.1038/nbt.1754 PMID: 21221095

28. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in bioinformatics 2013 Mar; 14(2):178–192. https://doi.org/10.1093/bib/bbs017 PMID: 22517427

29. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes, Chromosomes and Cancer 2011 May; 50(5):307–312. https://doi.org/10.1002/gcc.20854 PMID: 21305640

30. Office for National Statistics. 2011 Census: Ethnic group, local authorities in the United Kingdom*. 2013 11 October.

31. Gray LJ, Yates T, Davies MJ, Brady E, Webb DR, Sattar N, et al. Defining Obesity Cut-Off Points for Migrant South Asians. PloS one 2011; 6(10):e26464. https://doi.org/10.1371/journal.pone.0026464 PMID: 22039493

32. Lord K, Ibrahim K, Kumar S, Rudd N, Mitchell AJ, Symonds P. Measuring Trust in Healthcare Professionals—A Study of Ethnically Diverse UK Cancer Patients. Clinical Oncology 2011; 24(1):13–21. https://doi.org/10.1016/j.clon.2011.05.010 PMID: 21742474

33. Yeramian A, Moreno-bueno G, Dolcet X, Catasus L, Abal M, Colas E, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene 2013 Jan 24.; 32(4):403–413. https://doi.org/10.1038/onc.2012.76 PMID: 22430211
34. Oda K, Stokoe D, Taketani Y, McCormick F. High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma. Cancer Research 2005 Dec 1; 65(23):10669–10673. https://doi.org/10.1158/0008-5472.CAN-05-2620 PMID: 16322209

35. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell reports 2014 Jan 30; 6(2):377–387. https://doi.org/10.1016/j.celrep.2013.12.035 PMID: 24440717

36. Liang H-, Cheung L, Li J-, Ju Z-, Yu S-, Stemke-Hale K-. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Research 2012; 22:2120–2129. https://doi.org/10.1101/gr.137596.112 PMID: 23028188

37. Ogiwara H, Takahashi K, Sasaki M, Sasaki H, Kuroda T, Yoshida H, et al. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Cancer Cell 2019 Feb 11; 35(2):177–190.e8. https://doi.org/10.1016/j.ccell.2018.12.009 PMID: 30686770

38. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014 Jul 30; 5(14):5295–5303. https://doi.org/10.18632/oncotarget.2092 PMID: 24979463

39. Anglesio MS, Carey MS, Köbel M, MacKay H, Huntsman DG. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic Oncology 2011; 121(2):407–415. https://doi.org/10.1016/j.ygyno.2011.01.005 PMID: 21276610

40. Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Taft LJ. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome. Human Pathology 2017; 70:121–128. https://doi.org/10.1016/j.humpath.2017.10.022 PMID: 29107668

41. Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, et al. Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Annals of oncology: official journal of the European Society for Medical Oncology 2017 Jan 1; 28(1):96.

42. Frank A. Sinicrope, Nathan R. Foster, Harry H. Yoon, Thomas C. Smyrk, George P. Kim, Carmen J. Allegra, et al. Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. Journal of Clinical Oncology 2012 Feb 1; 30(4):406–412. https://doi.org/10.1200/JCO.2011.39.2563 PMID: 22203756

43. He EY, Hawkins NJ, Mak G, Roncolato F, Goldstein D, Liauw W, et al. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. The Oncologist 2016 May; 21(5):618–625. https://doi.org/10.1634/theoncologist.2015-0530 PMID: 27009937

44. Joehlin-Price et al. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecologic Oncology 2014; 133(1):43–47. https://doi.org/10.1016/j.ygyno.2014.01.017 PMID: 24444820

45. Slattery ML, Potter JD, Curtin K, Edwards S, Ma K, Anderson K, et al. Estrogens Reduce and Withdrawal of Estrogens Increase Risk of Microsatellite Instability-positive Colon Cancer. Cancer Research 2001 Jan 1; 61(1):126–130. PMID: 11196149

46. Issa JJ, Celano P, Ottaviano YL, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genetics 1994; 7(4):536–540. https://doi.org/10.1038/ng0894-536 PMID: 7951326

47. Sara A Byron, Michael Gartside, Matthew A Powell, Candice L Wellens, Feng Gao, David G Mutch, et al. FGFR2 Point Mutations in 466 Endometroid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. PLoS One 2012 Feb 1; 7(2):e30801. https://doi.org/10.1371/journal.pone.0030801 PMID: 22383975